Analysis of Japanese patients from the AUGMENT phase III study of lenalidomide + rituximab (R2) vs. rituximab + placebo in relapsed/refractory indolent non-Hodgkin lymphoma

2019 ◽  
Vol 111 (3) ◽  
pp. 409-416 ◽  
Author(s):  
Koji Izutsu ◽  
Yosuke Minami ◽  
Noriko Fukuhara ◽  
Yasuhito Terui ◽  
Tatsuro Jo ◽  
...  
Keyword(s):  
Hodgkin Lymphoma ◽  
Japanese Patients ◽  
Phase Iii ◽  
Non Hodgkin Lymphoma ◽  
Phase Iii Study

GADOLIN: Primary results from a phase III study of obinutuzumab plus bendamustine compared with bendamustine alone in patients with rituximab-refractory indolent non-Hodgkin lymphoma.

2015 ◽  
Vol 33 (15_suppl) ◽  
pp. LBA8502-LBA8502
Author(s):  
Laurie Helen Sehn ◽  
Neil Sun Chua ◽  
Jiri Mayer ◽  
Gregory Scott Dueck ◽  
Marek Trněný ◽  
...  
Keyword(s):  
Hodgkin Lymphoma ◽  
Phase Iii ◽  
Non Hodgkin Lymphoma ◽  
Phase Iii Study

Su2008 A PHASE III STUDY OF TEDUGLUTIDE IN ADULT JAPANESE PATIENTS WITH SHORT BOWEL SYNDROME–ASSOCIATED INTESTINAL FAILURE

2020 ◽  
Vol 158 (6) ◽  
pp. S-742
Author(s):  
Motoshi Wada ◽  
Tsunekazu Mizushima ◽  
Akira Sugita ◽  
Yuko Tazuke ◽  
Eri Udagawa ◽  
...  
Keyword(s):  
Short Bowel Syndrome ◽  
Intestinal Failure ◽  
Japanese Patients ◽  
Phase Iii ◽  
Short Bowel ◽  
Phase Iii Study
Sign in / Sign up

Export Citation Format

Share Document